Table 2.
Risk of various endpoints according to uric acid levels at randomization
| No. events | Crude rate per 100 py | Unadjusted HR (95% CI) | p‐value | Adjusted HR (95% CI) a | p‐value | |
|---|---|---|---|---|---|---|
| Cardiovascular death or worsening HF event b | ||||||
| Uric acid tertile | ||||||
| T1: <5.4 mg/dl | 150 | 9.7 (8.2–11.4) | 1.00 (reference) | 1.00 (reference) | ||
| T2: 5.4–6.7 mg/dl | 172 | 11.4 (9.7–13.2) | 1.15 (0.93–1.44) | 0.2 | 1.03 (0.82–1.29) | 0.83 |
| T3: 6.8–13.7 mg/dl | 250 | 18.9 (16.7–21.4) | 1.87 (1.52–2.29) | <0.0001 | 1.32 (1.06–1.66) | 0.01 |
| UA per 1 mg/dl unit increase | 1.19 (1.14–1.25) | <0.001 | 1.08 (1.03–1.14) | 0.0017 | ||
| Cardiovascular death | ||||||
| Uric acid tertile | ||||||
| T1: <5.4 mg/dl | 95 | 5.9 (4.8–7.2) | 1.00 (reference) | 1.00 (reference) | ||
| T2: 5.4–6.7 mg/dl | 83 | 5.2 (4.2–6.4) | 0.86 (0.64–1.16) | 0.33 | 0.77 (0.57–1.05) | 0.10 |
| T3: 6.8–13.7 mg/dl | 146 | 10.3 (8.7–12.1) | 1.69 (1.30–2.19) | <0.001 | 1.18 (0.89–1.58) | 0.25 |
| UA per 1 mg/dl unit increase | 1.18 (1.12–1.26) | <0.001 | 1.06 (0.99–1.14) | 0.07 | ||
| HF hospitalization | ||||||
| Uric acid tertile | ||||||
| T1: <5.4 mg/dl | 89 | 5.8 (4.7–7.1) | 1.00 (reference) | 1.00 (reference) | ||
| T2: 5.4–6.7 mg/dl | 119 | 7.9 (6.6–9.4) | 1.34 (1.02–1.77) | 0.04 | 1.17 (0.88–1.55) | 0.29 |
| T3: 6.8–13.7 mg/dl | 158 | 12.0 (10.2–14.0) | 1.96 (1.51–2.54) | <0.001 | 1.29 (0.97–1.72) | 0.08 |
| UA per 1 mg/dl unit increase | 1.20 (1.14–1.27) | <0.001 | 1.07 (1.00–1.14) | 0.04 | ||
| All‐cause mortality | ||||||
| Uric acid tertile | ||||||
| T1: <5.4 mg/dl | 122 | 7.6 (6.3–9.1) | 1.00 (reference) | 1.00 (reference) | ||
| T2: 5.4–6.7 mg/dl | 102 | 6.4 (5.3–7.7) | 0.83 (0.64–1.08) | 0.26 | 0.76 (0.58–0.99) | 0.05 |
| T3: 6.8–13.7 mg/dl | 166 | 11.7 (10.0–13.6) | 1.5(1.19–1.89) | 0.0007 | 1.09 (0.84–1.42) | 0.51 |
| UA per 1 mg/dl unit increase | 1.14 (1.08–1.21) | <0.001 | 1.03 (0.97–1.1) | 0.28 | ||
CI, confidence interval; HF, heart failure; HR, hazard ratio; py, person‐years; T, tertile.
Stratified by diabetes status and adjusted for the following baseline variables: history of HF hospitalization, treatment group assignment, age, sex, pulse, systolic blood pressure, body mass index, atrial fibrillation, diabetes, aetiology of HF, left ventricular ejection fraction, New York Heart Association functional classification, N‐terminal pro‐B‐type natriuretic peptide (log), estimated glomerular filtration rate, non‐loop diuretic use, loop diuretic use dose, and use of angiotensin‐converting enzyme inhibitor, angiotensin receptor blocker or angiotensin receptor–neprilysin inhibitor.
Worsening HF event includes unplanned HF hospitalization or urgent visit for worsening HF requiring intravenous diuretic therapy.